NEMECYS NEw MEdical CYbersecurity assessment and design Solutions
- Coordinator
- Sintef AS, Norway
- Runs
- 1 January 2023 to 31 December 2025
- Status
- Finished
- EU funding
- €4.2m
- Total cost
- €4.2m
- Partners
- 14 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101094323
What the project is doing
In the project's own words, from its summary on CORDIS.
The European health care system is moving toward personalised, distributed, and home-based services. This is made possible via new and improved connected medical devices (MDs) and in vitro diagnostic devices connected to the internet (together, CMDs), and will benefit health care providers in terms of reduced cost (fewer hospital beds) and improved service. Patients will see improved quality of life in terms of reduced travel time and reduced stress via treatment at home or where they want it.
However, for these benefits to be fully realised, the cybersecurity of CMDs needs to be ensured. NEMECYS will benefit practitioners such as cybersecurity communities, MD manufacturers, CMD scenario system integrators and CMD scenario operators (e.g. health care providers), with downstream benefits to patients and the wider public, through more cost-effective and efficient care enabled via effective and streamlined cybersecurity.
NEMECYS helps practitioners to (1) comply with MD regulations; (2) to be able to apply proportionate MD cybersecurity (too little security risks exposure, too much is costly and can obstruct clinical care) and (3) build in cybersecurity by design for both MDs and the connected scenarios they operate in. This is achieved by (1) providing recommendations for best practice and guidelines for MD cybersecurity by design, along with compliance assurance tooling; (2) providing a risk-benefit scheme to address cybersecurity risk balanced with clinical benefit; and (3) providing a set of specific tools to address MD cybersecurity by design and their deployment in connected scenarios.
The NEMECYS team has cybersecurity risk experts, two hospitals who are already implementing IoT and remote care-based scenarios, three medical device manufacturers, major computer science research players and experienced systems integrators. This team is ideally placed to ensure that NEMECYS can enable practitioners to apply the right security at the right place, at low cost.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Sintef AS | Trondheim | Norway | Coordinator |
| Bd Switzerland SARL | Eysins | Switzerland | Associatedpartner |
| Debiotech S.a. | Lausanne | Switzerland | Associatedpartner |
| Athens Technology Center Anonymi Viomichaniki Emporiki Kai Techniki Etaireia Efarmogon Ypsilis Technologias | Athina | Greece | Participant |
| Panepistimio Ioanninon | Ioannina | Greece | Participant |
| Information Catalyst SL | Xativa | Spain | Participant |
| Marina Salud SA | Denia-Alicante | Spain | Participant |
| Ribera Salud Tecnologias Sociedad Limitada | Valencia | Spain | Participant |
| Ibm Israel - Science and Technology Ltd | Petach Tikva | Israel | Participant |
| Ospedale San Raffaele SRL | Milano | Italy | Participant |
| Mode Sensors AS | Trondheim | Norway | Participant |
| Information Catalyst for Enterprise Ltd | Northwich Cheshire | United Kingdom | Associatedpartner |
| Pd Neurotechnology Ltd | London | United Kingdom | Associatedpartner |
| University of Southampton | Southampton | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI